Recent Advances and New Strategies in Targeting Plk1 for Anticancer Therapy

Trends in Pharmacological Sciences

Volumn 36, Issue 12, 2015, Pages 858-877

  Lee, Kyung S ^a   Burke, Terrence R ^b   Park, Jung Eun ^a   Bang, Jeong K ^c   Lee, Eunhye ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c Korea Basic Science Institute (KBSI)   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

BENZOLACTAM DERIVATIVE; BENZYLSTYRYL SULFONE; CYCLAPOLIN 1; DIAMINOPYRIMIDINE DERIVATIVE; DIHYDROPTERIDINONE DERIVATIVE; GSK 461364 A; HMN 214; IMIDAZOPYRIDINE DERIVATIVE; POLO LIKE KINASE 1; POLOXIN; POLOXIPAN; PROTEIN KINASE INHIBITOR; PURPUROGALLIN; PYRAZOLOQUINAZOLINE; RO 3280; SBE 13; TAK 960; THIOPHENE DERIVATIVE; THYMOQUINONE; THYMOQUINONE DERIVATIVE; UNCLASSIFIED DRUG; VOLASERTIB; ZK THIAZOLIDINONE; ANTINEOPLASTIC AGENT; CELL CYCLE PROTEIN; ONCOPROTEIN; POLO-LIKE KINASE 1; PROTEIN SERINE THREONINE KINASE;

ACUTE MYELOBLASTIC LEUKEMIA; ADVANCED CANCER; AMINO TERMINAL SEQUENCE; ANAPLASTIC THYROID CANCER; ASTROCYTOMA; BREAST CANCER; CANCER CELL LINE; CARBOXY TERMINAL SEQUENCE; COLORECTAL CANCER; DRUG EFFICACY; DRUG TARGETING; ENZYME ACTIVITY; ENZYME LOCALIZATION; ESOPHAGUS CANCER; GLIOBLASTOMA; GLIOMA; HEAD AND NECK CANCER; HUMAN; IC50; LEUKOPENIA; LIVER CELL CARCINOMA; LUNG CANCER; MALIGNANT NEOPLASTIC DISEASE; MELANOMA; MONOTHERAPY; NEUTROPENIA; NON SMALL CELL LUNG CANCER; NONHUMAN; OVARY CANCER; PANCREAS CANCER; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; REVIEW; SOLID TUMOR; STOMACH CANCER; ANIMAL; ANTAGONISTS AND INHIBITORS; ENZYMOLOGY; METABOLISM; MOLECULARLY TARGETED THERAPY; NEOPLASMS;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL CYCLE PROTEINS; HUMANS; MOLECULAR TARGETED THERAPY; NEOPLASMS; PROTEIN KINASE INHIBITORS; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS;

EID: 84949504308     PISSN: 01656147     EISSN: 18733735     Source Type: Journal    
DOI: 10.1016/j.tips.2015.08.013     Document Type: Review

References (153)

1. S.K. Hanks, and et al. The protein kinase family: conserved features and deduced phylogeny of the catalytic domains Science 241 1988 42 52
2. P. Lahiry, and et al. Kinase mutations in human disease: interpreting genotype-phenotype relationships Nat. Rev. Genet. 11 2010 60 74
3. P. Cohen, and D.R. Alessi Kinase drug discovery - what's next in the field? ACS Chem. Biol. 8 2013 96 104
4. I. Melnikova, and J. Golden Targeting protein kinases Nat. Rev. Drug Discov. 3 2004 993 994
5. L. Garuti, and et al. Polo-like kinases inhibitors Curr. Med. Chem. 19 2012 3937 3948
6. H. Yim Current clinical trials with polo-like kinase 1 inhibitors in solid tumors Anticancer Drugs 24 2013 999 1006
7. K. Strebhardt, and et al. Thoughts on the current assessment of Polo-like kinase inhibitor drug discovery Expert Opin. Drug Discov. 10 2015 1 8
8. H. Yim, and R.L. Erikson Plk1-targeted therapies in TP53- or RAS-mutated cancer Mutat. Res. Rev. Mutat. Res. 761 2014 31 39
9. V. Archambault, and D.M. Glover Polo-like kinases: conservation and divergence in their functions and regulation Nat. Rev. Mol. Cell Biol. 10 2009 265 275
10. F.A. Barr, and et al. Polo-like kinases and the orchestration of cell division Nat. Rev. Mol. Cell Biol. 5 2004 429 440
11. M. Petronczki, and et al. Polo on the rise - from mitotic entry to cytokinesis with Plk1 Dev. Cell 14 2008 646 659
12. S. Zitouni, and et al. Polo-like kinases: structural variations lead to multiple functions Nat. Rev. Mol. Cell Biol. 15 2014 433 452
13. A.E. Elia, and et al. Proteomic screen finds pSer/pThr-binding domain localizing Plk1 to mitotic substrates Science 299 2003 1228 1231
14. J.W. Hudson, and et al. Late mitotic failure in mice lacking Sak, a polo-like kinase Curr. Biol. 11 2001 441 446
15. Y.S. Seong, and et al. A spindle checkpoint arrest and a cytokinesis failure by the dominant-negative polo-box domain of Plk1 in U-2 OS cells J. Biol. Chem. 277 2002 32282 32293
16. G. de Carcer, and et al. Plk5, a polo box domain-only protein with specific roles in neuron differentiation and glioblastoma suppression Mol. Cell. Biol. 31 2011 1225 1239
17. G.C. Leung, and et al. The Sak polo-box comprises a structural domain sufficient for mitotic subcellular localization Nat. Struct. Biol. 9 2002 719 724
18. K. Kishi, and et al. Functional dynamics of Polo-like kinase 1 at the centrosome Mol. Cell. Biol. 29 2009 3134 3150
19. L. Arnaud, and et al. GFP tagging reveals human Polo-like kinase 1 at the kinetochore/centromere region of mitotic chromosomes Chromosoma 107 1998 424 429
20. R.M. Golsteyn, and et al. Cell cycle regulation of the activity and subcellular localization of Plk1, a human protein kinase implicated in mitotic spindle function J. Cell Biol. 129 1995 1617 1628
21. K.S. Lee, and et al. Plk is an M-phase-specific protein kinase and interacts with a kinesin-like protein, CHO1/MKLP-1 Mol. Cell. Biol. 15 1995 7143 7151
22. T.F. Burns, and et al. Silencing of the novel p53 target gene Snk/Plk2 leads to mitotic catastrophe in paclitaxel (taxol)-exposed cells Mol. Cell. Biol. 23 2003 5556 5571
23. E.M. Matthew, and et al. Replication stress, defective S-phase checkpoint and increased death in Plk2-deficient human cancer cells Cell Cycle 6 2007 2571 2578
24. E.M. Bahassi, and et al. Mammalian Polo-like kinase 3 (Plk3) is a multifunctional protein involved in stress response pathways Oncogene 21 2002 6633 6640
25. S. Xie, and et al. Genotoxic stress-induced activation of Plk3 is partly mediated by Chk2 Cell Cycle 1 2002 424 429
26. S. Xie, and et al. Plk3 functionally links DNA damage to cell cycle arrest and apoptosis at least in part via the p53 pathway J. Biol. Chem. 276 2001 43305 43312
27. S. Xie, and et al. Reactive oxygen species-induced phosphorylation of p53 on serine 20 is mediated in part by polo-like kinase-3 J. Biol. Chem. 276 2001 36194 36199
28. S. Xie, and et al. Regulation of cell cycle checkpoints by polo-like kinases Oncogene 24 2005 277 286
29. C. Helmke, and et al. The role of Plk3 in oncogenesis Oncogene 2015 10.1038/onc.2015.105 Published online April 27, 2015
30. D.P. Seeburg, and et al. Polo-like kinases in the nervous system Oncogene 24 2005 292 298
31. D.P. Seeburg, and M. Sheng Activity-induced Polo-like kinase 2 is required for homeostatic plasticity of hippocampal neurons during epileptiform activity J. Neurosci. 28 2008 6583 6591
32. 2+- and integrin-binding protein and are regulated dynamically with synaptic plasticity EMBO J. 18 1999 5528 5539
33. R. Habedanck, and et al. The Polo kinase Plk4 functions in centriole duplication Nat. Cell Biol. 7 2005 1140 1146
34. E.A. Nigg Centrosome duplication: of rules and licenses Trends Cell Biol. 17 2007 215 221
35. L.Y. Lu, and et al. Polo-like kinase 1 is essential for early embryonic development and tumor suppression Mol. Cell. Biol. 28 2008 6870 6876
36. S. Ma, and et al. Role of Plk2 (Snk) in mouse development and cell proliferation Mol. Cell. Biol. 23 2003 6936 6943
37. Y. Yang, and et al. Polo-like kinase 3 functions as a tumor suppressor and is a negative regulator of hypoxia-inducible factor-1 alpha under hypoxic conditions Cancer Res. 68 2008 4077 4085
38. A.J. Holland, and et al. The autoregulated instability of Polo-like kinase 4 limits centrosome duplication to once per cell cycle Genes Dev. 26 2012 2684 2689
39. A.E. Elia, and et al. The molecular basis for phospho-dependent substrate targeting and regulation of Plks by the polo-box domain Cell 115 2003 83 95
40. D.M. Lowery, and et al. Structure and function of polo-like kinases Oncogene 24 2005 248 259
41. D.M. Lowery, and et al. The Polo-box domain: a molecular integrator of mitotic kinase cascades and Polo-like kinase function Cell Cycle 3 2004 128 131
42. J.E. Park, and et al. Feed-forward mechanism of converting biochemical cooperativity to mitotic processes at the kinetochore plate Proc. Natl. Acad. Sci. U.S.A. 108 2011 8200 8205
43. J.E. Park, and et al. Polo-box domain: a versatile mediator of polo-like kinase function Cell. Mol. Life Sci. 67 2010 1957 1970
44. K.Y. Cheng, and et al. The crystal structure of the human polo-like kinase-1 polo box domain and its phospho-peptide complex EMBO J. 22 2003 5757 5768
45. M. Kothe, and et al. Selectivity-determining residues in Plk1 Chem. Biol. Drug Des. 70 2007 540 546
46. J. Xu, and et al. Structural basis for the inhibition of Polo-like kinase 1 Nat. Struct. Mol. Biol. 20 2013 1047 1053
47. V. Archambault, and et al. Understanding the Polo kinase machine Oncogene 2015 10.1038/onc.2014.451 Published online January 26, 2015
48. E.F. Johnson, and et al. Pharmacological and functional comparison of the polo-like kinase family: insight into inhibitor and substrate specificity Biochemistry 46 2007 9551 9563
49. J-E. Park, and et al. Direct quantification of polo-like kinase 1 activity in cells and tissues using a highly sensitive and specific ELISA assay Proc. Natl. Acad. Sci. U.S.A. 106 2009 1725 1730
50. W. Reindl, and et al. Development of high-throughput assays based on fluorescence polarization for inhibitors of the polo-box domains of polo-like kinases 2 and 3 Anal. Biochem. 395 2009 189 194
51. W. Reindl, and et al. A high-throughput assay based on fluorescence polarization for inhibitors of the polo-box domain of polo-like kinase 1 Anal. Biochem. 383 2008 205 209
52. K.S. Lee, and et al. Mutation of the polo-box disrupts localization and mitotic functions of the mammalian polo kinase Plk Proc. Natl. Acad. Sci. U.S.A. 95 1998 9301 9306
53. K. Strebhardt, and A. Ullrich Targeting polo-like kinase 1 for cancer therapy Nat. Rev. Cancer 6 2006 321 330
54. L. Macurek, and et al. Polo-like kinase-1 is activated by aurora A to promote checkpoint recovery Nature 455 2008 119 123
55. M.A. van Vugt, and et al. Polo-like kinase 1 controls recovery from a G2 DNA damage-induced arrest in mammalian cells Mol. Cell 15 2004 799 811
56. M. Raab, and et al. Toxicity modelling of Plk1-targeted therapies in genetically engineered mice and cultured primary mammalian cells Nat. Commun. 2 2011 395 405
57. I.B. Weinstein Addiction to oncogenes - the Achilles heal of cancer Science 297 2002 63 64
58. J. Luo, and et al. Principles of cancer therapy: oncogene and non-oncogene addiction Cell 136 2009 823 837
59. H.R. McMurray, and et al. Synergistic response to oncogenic mutations defines gene class critical to cancer phenotype Nature 453 2008 1112 1116
60. X. Liu, and et al. Normal cells, but not cancer cells, survive severe Plk1 depletion Mol. Cell. Biol. 26 2006 2093 2108
61. S. Sur, and et al. A panel of isogenic human cancer cells suggests a therapeutic approach for cancers with inactivated p53 Proc. Natl. Acad. Sci. U.S.A. 106 2009 3964 3969
62. Y. Degenhardt, and et al. Sensitivity of cancer cells to Plk1 inhibitor GSK461364A is associated with loss of p53 function and chromosome instability Mol. Cancer Ther. 9 2010 2079 2089
63. R. Guan, and et al. Small interfering RNA-mediated Polo-like kinase 1 depletion preferentially reduces the survival of p53-defective, oncogenic transformed cells and inhibits tumor growth in animals Cancer Res. 65 2005 2698 2704
64. S.I. King, and et al. Immunohistochemical detection of Polo-like kinase-1 (PLK1) in primary breast cancer is associated with TP53 mutation and poor clinical outcom Breast Cancer Res. 14 2012 R40
65. J. Luo, and et al. A genome-wide RNAi screen identifies multiple synthetic lethal interactions with the Ras oncogene Cell 137 2009 835 848
66. R. Knecht, and et al. PLK (polo-like kinase), a new prognostic marker for oropharyngeal carcinomas Int. J. Cancer 89 2000 535 536
67. R. Knecht, and et al. Prognostic significance of polo-like kinase (PLK) expression in squamous cell carcinomas of the head and neck Cancer Res. 59 1999 2794 2797
68. K. Strebhardt, and et al. Prognostic value of polo-like kinase expression in melanomas JAMA 283 2000 479 480
69. L. Kneisel, and et al. Expression of polo-like kinase (PLK1) in thin melanomas: a novel marker of metastatic disease J. Cutan. Pathol. 29 2002 354 358
70. R. Elez, and et al. Tumor regression by combination antisense therapy against Plk1 and Bcl-2 Oncogene 22 2003 69 80
71. M. Steegmaier, and et al. BI 2536, a potent and selective inhibitor of polo-like kinase 1, inhibits tumor growth in vivo Curr. Biol. 17 2007 316 322
72. B. Spankuch-Schmitt, and et al. Effect of RNA silencing of polo-like kinase-1 (PLK1) on apoptosis and spindle formation in human cancer cells J. Natl. Cancer Inst. 94 2002 1863 1877
73. M. Nogawa, and et al. Intravesical administration of small interfering RNA targeting PLK-1 successfully prevents the growth of bladder cancer J. Clin. Invest. 115 2005 978 985
74. P. Smith, and et al. Epigenetic inactivation implies a tumor suppressor function in hematologic malignancies for Polo-like kinase 2 but not Polo-like kinase 3 Cell Cycle 5 2006 1262 1264
75. S.M. Yun, and et al. Structural and functional analyses of minimal phosphopeptides targeting the polo-box domain of polo-like kinase 1 Nat. Struct. Mol. Biol. 16 2009 876 882
76. M. Kothe, and et al. Structure of the catalytic domain of human polo-like kinase 1 Biochemistry 46 2007 5960 5971
77. M.S. Cohen, and et al. Structural bioinformatics-based design of selective, irreversible kinase inhibitors Science 308 2005 1318 1321
78. K.S. Lee, and R.L. Erikson Plk is a functional homolog of Saccharomyces cerevisiae Cdc5, and elevated Plk activity induces multiple septation structures Mol. Cell. Biol. 17 1997 3408 3417
79. S. Keppner, and et al. Identification and validation of a potent type II inhibitor of inactive polo-like kinase 1 ChemMedChem 4 2009 1806 1809
80. Y. Liu, and N.S. Gray Rational design of inhibitors that bind to inactive kinase conformations Nat. Chem. Biol. 2 2006 358 364
81. C. Pargellis, and et al. Inhibition of p38 MAP kinase by utilizing a novel allosteric binding site Nat. Struct. Biol. 9 2002 268 272
82. W. Yang, and et al. Design, synthesis and biological evaluation of bis-aryl ureas and amides based on 2-amino-3-purinylpyridine scaffold as DFG-out B-Raf kinase inhibitors Eur. J. Med. Chem. 89 2015 581 596
83. J. Dietrich, and et al. Application of a novel [3+2] cycloaddition reaction to prepare substituted imidazoles and their use in the design of potent DFG-out allosteric B-Raf inhibitors Bioorg. Med. Chem. Lett. 18 2010 292 304
84. K. Gumireddy, and et al. ON01910, a non-ATP-competitive small molecule inhibitor of Plk1, is a potent anticancer agent Cancer Cell 7 2005 275 286
85. P. Lenart, and et al. The small-molecule inhibitor BI 2536 reveals novel insights into mitotic roles of polo-like kinase 1 Curr. Biol. 17 2007 304 315
86. M. Raab, and et al. Quantitative chemical proteomics reveals a Plk1 inhibitor-compromised cell death pathway in human cells Cell Res. 24 2014 1141 1145
87. P. Ciceri, and et al. Dual kinase-bromodomain inhibitors for rationally designed polypharmacology Nat. Chem. Biol. 10 2014 305 312
88. V. Maire, and et al. Polo-like kinase 1: a potential therapeutic option in combination with conventional chemotherapy for the management of patients with triple-negative breast cancer Cancer Res. 73 2013 813 823
89. C. Lund-Andersen, and et al. PLK1-inhibition can cause radiosensitization or radioresistance dependent on the treatment schedule Radiother. Oncol. 110 2014 355 361
90. D. Rudolph, and et al. BI 6727, a Polo-like kinase inhibitor with improved pharmacokinetic profile and broad antitumor activity Clin. Cancer Res. 15 2009 3094 3102
91. D. Rudolph, and et al. Efficacy and mechanism of action of volasertib, a potent and selective inhibitor of Polo-like kinases, in preclinical models of acute myeloid leukemia J. Pharmacol. Exp. Ther. 352 2015 579 589
92. A.G. Gilmartin, and et al. Distinct concentration-dependent effects of the polo-like kinase 1-specific inhibitor GSK461364A, including differential effect on apoptosis Cancer Res. 69 2009 6969 6977
93. K.A. Emmitte, and et al. Discovery of thiophene inhibitors of polo-like kinase Bioorg. Med. Chem. Lett. 19 2009 1018 1021
94. M.A. Russo, and et al. The PLK1 inhibitor GSK461364A is effective in poorly differentiated and anaplastic thyroid carcinoma cells, independent of the nature of their driver mutations Thyroid 23 2013 1284 1293
95. D. Olmos, and et al. Phase I study of GSK461364, a specific and competitive Polo-like kinase 1 inhibitor, in patients with advanced solid malignancies Clin. Cancer Res. 17 2011 3420 3430
96. S. Chen, and et al. Identification of novel, potent and selective inhibitors of Polo-like kinase 1 Bioorg. Med. Chem. Lett. 22 2012 1247 1250
97. N.N. Wang, and et al. Molecular targeting of the oncoprotein PLK1 in pediatric acute myeloid leukemia: RO3280, a novel PLK1 inhibitor, induces apoptosis in leukemia cells Int. J. Mol. Sci. 16 2015 1266 1292
98. U. Peters, and et al. Probing cell-division phenotype space and Polo-like kinase function using small molecules Nat. Chem. Biol. 2 2006 618 626
99. D.W. Bowles, and et al. Phase I study of oral rigosertib (ON 01910.Na), a dual inhibitor of the PI3K and Plk1 pathways, in adult patients with advanced solid malignancies Clin. Cancer Res. 20 2014 1656 1665
100. M.V. Reddy, and et al. Discovery of a clinical stage multi-kinase inhibitor sodium (E)-2-{2-methoxy-5-[(2′,4′,6′-trimethoxystyrylsulfonyl)methyl]phenylamino}acetate (ON 01910.Na): synthesis, structure-activity relationship, and biological activity J. Med. Chem. 54 2011 6254 6276
101. L.L. Garland, and et al. A phase I pharmacokinetic study of HMN-214, a novel oral stilbene derivative with polo-like kinase-1-interacting properties, in patients with advanced solid tumors Clin. Cancer Res. 12 2006 5182 5189
102. M. Takagi, and et al. In vivo antitumor activity of a novel sulfonamide, HMN-214, against human tumor xenografts in mice and the spectrum of cytotoxicity of its active metabolite, HMN-176 Invest. New Drugs 21 2003 387 399
103. M.W. Karaman, and et al. A quantitative analysis of kinase inhibitor selectivity Nat. Biotechnol. 26 2008 127 132
104. S. Keppner, and et al. Biological impact of freezing Plk1 in its inactive conformation in cancer cells Cell Cycle 9 2010 761 773
105. M.R. Arkin, and et al. Small-molecule inhibitors of protein-protein interactions: progressing toward the reality Chem. Biol. 21 2014 1102 1114
106. F. Liu, and et al. Serendipitous alkylation of a Plk1 ligand uncovers a new binding channel Nat. Chem. Biol. 7 2011 595 601
107. H.M. Shan, and et al. Crystal structure of the polo-box domain of polo-like kinase 2 Biochem. Biophys. Res. Commun. 456 2015 780 784
108. J.H. Kim, and et al. Structural analysis of the polo-box domain of human Polo-like kinase 2 Proteins 83 2015 1201 1210
109. W. Reindl, and et al. Inhibition of polo-like kinase 1 by blocking polo-box domain-dependent protein-protein interactions Chem. Biol. 15 2008 459 466
110. J. Yuan, and et al. Polo-box domain inhibitor poloxin activates the spindle assembly checkpoint and inhibits tumor growth in vivo Am. J. Pathol. 179 2011 2091 2099
111. Y. Zhou, and et al. Thymoquinone and Poloxin are slow-irreversible inhibitors to human Polo-like kinase 1 Polo-box domain J. Med. Coll. PLA 25 2010 136 142
112. K.S. Lee, and J.R. Idle Pinning down the polo-box domain Chem. Biol. 15 2008 415 416
113. W. Reindl, and et al. A pan-specific inhibitor of the polo-box domains of polo-like kinases arrests cancer cells in mitosis Chembiochem 10 2009 1145 1148
114. Z. Yin, and et al. Thymoquinone blocks pSer/pThr recognition by Plk1 Polo-box domain as a phosphate mimic ACS Chem. Biol. 8 2013 303 308
115. N. Watanabe, and et al. Deficiency in chromosome congression by the inhibition of Plk1 polo box domain-dependent recognition J. Biol. Chem. 284 2009 2344 2353
116. C. Liao, and et al. Exploring potential binding modes of small drug-like molecules to the polo-box domain of human polo-like kinase 1 ACS Med. Chem. Lett. 1 2010 110 114
117. F. Liu, and et al. Identification of high affinity polo-like kinase 1 (Plk1) polo-box domain binding peptides using oxime-based diversification ACS Chem. Biol. 7 2012 805 810
118. F. Liu, and et al. Peptoid-peptide hybrid ligands targeting the polo box domain of polo-like kinase 1 Chembiochem 13 2012 1291 1296
119. P. Sledz, and et al. High-throughput interrogation of ligand binding mode using a fluorescence-based assay Angew. Chem. 51 2012 7680 7683
120. P. ͆ledź, and et al. From crystal packing to molecular recognition: prediction and discovery of a binding site on the surface of Polo-like kinase 1 Angew. Chem. Int. Ed. Engl. 50 2011 4003 4006
121. Y.S. Tan, and et al. Using ligand-mapping simulations to design a ligand selectively targeting a cryptic surface pocket of polo-like kinase 1 Angew. Chem. 51 2012 10078 10081
122. W.J. Qian, and et al. Non-proteinogenic amino acids in the pThr-2 position of a pentamer peptide that confer high binding affinity for the polo box domain (PBD) of polo-like kinase 1 (Plk1) Bioorg. Med. Chem. Lett. 22 2012 7306 7308
123. R.N. Murugan, and et al. Exploring the binding nature of pyrrolidine pocket-dependent interactions in the polo-box domain of polo-like kinase 1 PLoS ONE 8 2013 e80043
124. F. Liu, and et al. Preparation of orthogonally protected (2S, 3R)-2-amino-3-methyl-4-phosphonobutyric acid (Pmab) as a phosphatase-stable phosphothreonine mimetic and its use in the synthesis of polo-box domain-binding peptides Tetrahydron 65 2009 9673 9679
125. W.J. Qian, and et al. Mono-anionic phosphopeptides produced by unexpected histidine alkylation exhibit high plk1 polo-box domain-binding affinities and enhanced antiproliferative effects in hela cells Biopolymers 102 2014 444 455
126. W. Qian, and et al. Effects on polo-like kinase 1 polo-box domain binding affinities of peptides incurred by structural variation at the phosphoamino acid position Bioorg. Med. Chem. 21 2013 3996 4003
127. W.J. Qian, and T.R. Burke Jr Mitsunobu mischief: neighbor-directed histidine N(tau)-alkylation provides access to peptides containing selectively functionalized imidazolium heterocycles Org. Biomol. Chem. 13 2015 4221 4225
128. R.N. Murugan, and et al. Development of cyclic peptomer inhibitors targeting the polo-box domain of polo-like kinase 1 Bioorg. Med. Chem. 21 2013 2623 2634
129. W-J. Qian, and et al. Neighbor-directed histidine N(τ)-alkylation: a route to imidazolium-containing phosphopeptide macrocycles Biopolymers Pept. Sci. 2015 10.1002/bip.22698 Publishd online July 7, 2015
130. K.J. Cox, and et al. Tinkering outside the kinase ATP box: allosteric (type IV) and bivalent (type V) inhibitors of protein kinases Future Med. Chem. 3 2011 29 43
131. M. Janning, and W. Fiedler Volasertib for the treatment of acute myeloid leukemia: a review of preclinical and clinical development Future Oncol. 10 2014 1157 1165
132. W.M. Stadler, and et al. An open-label, single-arm, phase 2 trial of the Polo-like kinase inhibitor volasertib (BI 6727) in patients with locally advanced or metastatic urothelial cancer Cancer 120 2014 976 982
133. H. Döhner, and et al. Randomized, phase 2 trial of low-dose cytarabine with or without volasertib in AML patients not suitable for induction therapy Blood 124 2014 1426 1433
134. Z. Zhao, and et al. p53 loss promotes acute myeloid leukemia by enabling aberrant self-renewal Genes Dev. 24 2010 1389 1402
135. G. Hu, and et al. P53 gene mutations in acute myelogenous leukaemia Br. J. Haematol. 81 1992 489 494
136. J.M. Slingerland, and et al. Mutation of the p53 gene in human acute myelogenous leukemia Blood 77 1991 1500 1507
137. Y.H. Kang, and et al. Self-regulated Plk1 recruitment to kinetochores by the Plk1-PBIP1 interaction is critical for proper chromosome segregation Mol. Cell 24 2006 409 422
138. J.M. Schvartzman, and et al. Mitotic chromosomal instability and cancer: mouse modelling of the human disease Nat. Rev. Cancer 10 2010 102 115
139. R. Pellegrino, and et al. Oncogenic and tumor suppressive roles of polo-like kinases in human hepatocellular carcinoma Hepatology 51 2010 857 868
140. W. Dai, and et al. PRK, a cell cycle gene localized to 8p21, is downregulated in head and neck cancer Genes Chromosomes Cancer 27 2000 332 336
141. B. Li, and et al. prk, a cytokine-inducible human protein serine/threonine kinase whose expression appears to be down-regulated in lung carcinomas J. Biol. Chem. 271 1996 19402 19408
142. M.A. Ko, and et al. Plk4 haploinsufficiency causes mitotic infidelity and carcinogenesis Nat. Genet. 37 2005 883 888
143. J.C. Macmillan, and et al. Comparative expression of the mitotic regulators SAK and PLK in colorectal cancer Ann. Surg. Oncol. 8 2001 729 740
144. M. Marina, and H.I. Saavedra Nek2 and Plk4: prognostic markers, drivers of breast tumorigenesis and drug resistance Front. Biosci. 19 2014 352 365
145. M.O. Duffey, and et al. Discovery of a potent and orally bioavailable benzolactam-derived inhibitor of Polo-like kinase 1 (MLN0905) J. Med. Chem. 55 2012 197 208
146. A. Santamaria, and et al. Use of the novel Plk1 inhibitor ZK-thiazolidinone to elucidate functions of Plk1 in early and late stages of mitosis Mol. Biol. Cell 18 2007 4024 4036
147. C. McInnes, and et al. Inhibitors of Polo-like kinase reveal roles in spindle-pole maintenance Nat. Chem. Biol. 2 2006 608 617
148. Y. Sato, and et al. Imidazopyridine derivatives as potent and selective Polo-like kinase (PLK) inhibitors Bioorg. Med. Chem. Lett. 19 2009 4673 4678
149. I. Beria, and et al. NMS-P937, a 4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline derivative as potent and selective Polo-like kinase 1 inhibitor Bioorg. Med. Chem. Lett. 21 2011 2969 2974
150. B. Valsasina, and et al. NMS-P937, an orally available, specific small-molecule polo-like kinase 1 inhibitor with antitumor activity in solid and hematologic malignancies Mol. Cancer Ther. 11 2012 1006 1016
151. Y. Hikichi, and et al. TAK-960, a novel, orally available, selective inhibitor of polo-like kinase 1, shows broad-spectrum preclinical antitumor activity in multiple dosing regimens Mol. Cancer Ther. 11 2012 700 709
152. D.L. Aubele, and et al. Selective and brain-permeable polo-like kinase-2 (Plk-2) inhibitors that reduce alpha-synuclein phosphorylation in rat brain ChemMedChem 8 2013 1295 1313
153. D.E. Kim, and et al. Protein structure prediction and analysis using the Robetta server Nucleic Acids Res. 32 2004 W526 W531